Table 2.

Unadjusted univariate logistic regression analyses of the association of survivor characteristics with being accompanied by a parent to the first survivorship clinic visit

Characteristic	Frequency of parental accompaniment N (%)	OR (95% CI)	p value
Sociodemographic
Age at first survivorship clinic visit, years
25.0–39.99	12 (21.4%)	Ref.
18.0–24.99	65 (58.0%)	5.07 (2.42, 10.63)	<0.0001
Sex
Female	47 (46.1%)	Ref.
Male	30 (45.5%)	0.98 (0.52, 1.82)	0.94
Insurance
Private	55 (45.1%)	Ref.
Public/self/none	18 (46.2%)	1.04 (0.51, 2.15)	0.91
Married
Yes	0 (0%)	Ref.
No	77 (52.0%)	>999.999 (<0.001, >999.999)	0.96
Cancer diagnosis and treatment
Age at diagnosis, per year	-	1.00 (0.94, 1.06)	0.91
Duration treatment, per year	-	0.88 (0.73, 1.07)	0.21
Less time elapsed since treatment, per year	-	1.09 (1.04, 1.15)	<0.001
Diagnosis
Leukemia/lymphoma	47 (44.3%)	Ref.
Central nervous system (CNS) tumor	12 (75.0%)	3.77 (1.14, 12.44)	0.030
Sarcoma/other non-CNS solid tumor	18 (39.1%)	0.81 (0.40, 1.63)	0.55
Cranial radiation
No	57 (42.9%)	Ref.
Yes	20 (57.1%)	1.78 (0.84, 3.77)	0.13
Treatment intensitya
4 - Most intensive	10 (34.5%)	Ref.
3 - Very intensive	30 (48.4%)	1.78 (0.71, 4.44)	0.22
1 - Least or 2 - moderately intensive	37 (48.1%)	1.76 (0.72, 4.27)	0.21
Late effects of cancer treatment
Number of medical late effects
≥2	54 (44.3%)	Ref.
0–1	23 (50.0%)	1.26 (0.64, 2.48)	0.51
Any medical late effect grade 3 or 4b
No	43 (47.3%)	Ref.
Yes	34 (44.2%)	0.88 (0.48, 1.62)	0.69
Impaired neurocognitive functioningc
No	62 (44.6%)	Ref.
Yes	15 (51.7%)	1.33 (0.60, 2.97)	0.48
Emotional distressd
No	46 (48.9%)	Ref.
Yes	31 (41.9%)	0.75 (0.41, 1.39)	0.36

CNS central nervous system

^aScaled using the Intensity of Treatment Rating Scale 3.0¹⁶

^bGraded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)¹⁷

^cMeasured with the Behavior Rating Inventory of Executive Function (BRIEF)-Global Executive Composite (before 2016) or the Patient-Reported Outcomes Measurement Information System (PROMIS)-Cognitive Function (after 2016)^18,22

^dMeasured with Brief Symptom Inventory-18 (BSI-18)-Global Severity Index (before 2016) or the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Profile (after 2016)^22,23